Patents by Inventor Albert Assad

Albert Assad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for treatment of hematological diseases
    Patent number: 11324749
    Abstract: The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: May 10, 2022
    Assignee: Incyte Corporation
    Inventor: Albert Assad
  • COMBINATION THERAPY FOR TREATMENT OF HEMATOLOGICAL DISEASES
    Publication number: 20200129517
    Abstract: The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Inventor: Albert Assad
  • Dosing Regimen for the Treatment of PI3K Related Disorders
    Publication number: 20190365764
    Abstract: The present application provides methods of treating PI3K? related disorders using pyrazolopyrimidine derivatives.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 5, 2019
    Inventors: Krishnaswamy Yeleswaram, Albert Assad, Xuejun Chen
  • Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
    Patent number: 9498467
    Abstract: This invention relates to JAK selective inhibitors for use in treatment of chronic neutrophilic leukemia and atypical chronic myeloid leukemia in patients.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: November 22, 2016
    Assignee: Incyte Corporation
    Inventors: Lance Howard Leopold, Albert Assad
  • Treatment of precancerous lesions with Sanguinaria Canadensis Extract/Compounded Extract
    Publication number: 20160058817
    Abstract: The present invention relates to a novel extract of the plant Sanguinaria Canadensis (SC) in combination with steroids and/or non-steroidal anti-inflammatory compounds, methods of preparation thereof, and to its use. More specifically, the invention relates to the preparation of a solubilized form of SC consisting of its isoquinolone alkaloids, sanguinarine and chelerythrine, compounded with topical steroids (hydrocortisone, triamcinolone acetonide, betamethasone, betamethasone diproprionate, methylprednisolone acetonate types, et al) and/or non-steroidal anti-inflammatory compounds. This application claims priority to U.S. patent application No. 61/870,227, filed Aug. 26, 2013, the contents of which, in part, are incorporated herein.
    Type: Application
    Filed: August 26, 2014
    Publication date: March 3, 2016
    Inventors: Stephen K. Richardson, Albert Assad
  • TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
    Publication number: 20150342952
    Abstract: This invention relates to JAK selective inhibitors for use in treatment of chronic neutrophilic leukemia and atypical chronic myeloid leukemia in patients.
    Type: Application
    Filed: May 29, 2015
    Publication date: December 3, 2015
    Applicant: INCYTE CORPORATION
    Inventors: Lance Howard Leopold, Albert Assad